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This is a commentary and an opinion paper attempting a critical reassessment of the
methods and practices of epilepsy research as we see it. The enormous progress in the
field of epilepsy in recent years is a cause of celebration. Advances have been made on
most fronts, and the position of patients with epilepsy in society has greatly improved.
However, there have also been culs-de-sac and dead ends of modern science and clini-
cal practice which are also intriguing. It may be true that we can learn more from our
mistakes than fromour successes. In this opinion paper, we have listed some of the suc-
cesses and some of the failures of past epilepsy practice, and also areas of current prac-
tice and theory which we feel are likely to prove mistaken. The underlying reasons for
misdirected practices and theories include, in our view, the influence of fashion, bad
science, and the bureaucracies of practice and academic medicine. As a result, some
findings are far from objective. Recognition is the first step to remediation, and hope-
fully future research will minimize some of the pitfalls mentioned in this article and
bring the “End of Epilepsy,” as defined and predicted by Oswei Temkin, closer than it
is today.
KEY WORDS: Epilepsy research, Scientific progress, End of epilepsy?, Anatomy of
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When we were invited to write this article for Epilepsia
Open, the new International League Against Epilepsy
(ILAE) journal, we felt apprehensive. We have just com-
pleted a book entitled The End of Epilepsy? which is an
account and critique of the history of epilepsy since 1860.1
In this, we outlined what we believe are landmarks in the
tremendous progress that epilepsy has made in these
150 years and the negative aspects of this history. The title
of our book is based on the final chapter of Oswei Temkin’s
definitive text on the history of epilepsy,2 in which he won-
dered whether the advance of science and of culture, in the
post-Jackson era, would mean that epilepsy would cease to
be “a paradigm of the suffering of both body and soul in dis-
ease.”
The positives certainly greatly outweigh the negatives,
and the result is that epilepsy now holds a privileged posi-
tion in the pantheon of neurology. Epilepsy is, at least in
societies that offer their citizens sufficient health care
resources, the most treatable of the severe chronic brain dis-
eases. Around 80% of all patients will become and remain
free of seizures after a course of usually well-tolerated
drugs, as a series of long-term studies have shown3 (Fig. 1).
Admittedly, not all patients become completely seizure
free, but of those who do not, many have fewer or less-
severe seizures during continued treatment. Emergency care
is readily available in kindergartens, in schools, and at work
and elsewhere. Compare these good outcomes with the out-
comes of people with stroke, encephalitis, brain tumors,
traumatic brain injury, Parkinson’s disease, or Alzheimer’s
dementia, which are all common severe brain diseases, and
which have less satisfactory treatment and a poorer chance
of recovery or longevity. It is clear that, over the period
reviewed in the book, enormous advances have been made.
Identifying which have been the most important steps is
obviously to an extent subjective. In Table 1, we list
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medical therapeutic and investigatory advances in the 20th
and 21st centuries that we believe have had the most impact
for treatment.
Our purpose is not to provide a fully referenced medical
review, but a critical commentary on the methods and prac-
tices of current and past epilepsy research. We have only
sparsely added key references for what we think are the
most important facts mentioned. The purpose of critical
reassessment is not to negate research and attempts to pro-
gress but to redirect them in possibly more useful directions.
Another point, worth stressing, is that social changes have
also been very impressive, and indeed in our book we sug-
gest—perhaps to some, provocatively—that the achieve-
ments on the social side have in fact been more important
than those in medicine. It is these social aspects that Temkin
emphasized, and they are as important a component as the
medical advances are in “ending the falling sickness.” Soci-
ety now has a more sympathetic understanding of the plight
of patients with severe epilepsy; there is less stigma, better
integration, better opportunities, better social care,
including rehabilitation, and far fewer social restrictions
and prejudices. These societal aspects and attitudes have
improved but are certainly not fully resolved, and they still
have a daily impact on people with epilepsy that should not
be underestimated.
However, in writing our book, we also came to realize
that many medical theories and practices strongly held in
the past have lost much of their appeal in later years and
have become discredited. These were furthermore not all
“prescientific” topics, but in fact many were made in the
name of science. Illustrative examples of such theories
and practices, which were widely accepted during some
periods of time in the last 100 years but then were much
less appreciated by later generations, are shown in
Table 2.
Today’s Theories and Practices
Which May NotWithstand the
Test of Time
It is also clear that, even in our scientific era, we are not
immune to erroneous theories or practices and that inevita-
bly areas of our contemporary practice will be proved incor-
rect in future decades. We have listed 10 theories or
practices that are, in our view, good candidates for being
rejected as erroneous in the future (Table 3). Of course, this
is a speculative list, and illustrative only, and certainly not
comprehensive; notwithstanding these cautions, our outline
justification for inclusion in the list is as follows.
Current drug discovery
Many drugs have been and continue to be based on
physicochemical manipulation of current drug structure,
often with the primary goal of maintaining patent protec-
tion and commercial advantage. These manipulations
result largely in “me-too” drugs with similar efficacy
rather than in a fundamental change to much-needed,
substantially more effective or better-tolerated drugs com-
pared with current medications.4,5 A much more promising
method, currently gaining momentum, is to design drugs
to modify a molecular target presumed to be involved in
seizure generation.4,5 Such target-based strategies offer the
potential for more fundamental advance than simply
manipulating the structure of existing drugs. However, in
practice, there have been some notable problems. Target-
based design depends on the validity of the target. Theo-
ries of seizure generation have often been shown to be
overly simplistic at best or completely false at worse. It
has also been clear that, to date at least, drugs designed to
act at one simple target have not proved more useful in
clinical practice. Finally, the targets have often been deter-
mined after the antiseizure effect of a drug has been
noticed. In practice, most current drugs are discovered by
screening and their mechanisms identified post hoc. It is
Figure 1.
Complete seizure remission in epilepsy. About 60% of people with
new-onset epilepsy enter a remission of at least 5 years after stop-
ping AEDs. Roughly 80% enter a remission of at least 5 years on or
off AEDs. Unfortunately, the 20% with persistent seizures and
often additional brain disease that is responsible for the epilepsy
have created the public image of an incurable condition (personal
communication: Matti Sillanp€a€a and Maiju Saarinen).
Epilepsia Open ILAE
Key Points
• The anatomy of the progress in epilepsy in the past
century
• The history of errors in the practice and the science of
epilepsy
• The change in public attitude and societal practice in
the last century
• The role of economics, fashion, and bureaucracies in
epilepsy and its research
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reasonable to expect that the discovery of specific targets
makes precision research and medicine in epilepsy possi-
ble as opposed to relying on a limited armamentarium of
mostly acute-seizure mass screening tests in a nonspecific
way as we often do now. Another important issue is that
our current drugs are “antiseizure,” not “antiepilepsy,”
medications, and there has been no progress in finding
medications that prevent epileptogenesis.
Table 1. Some notable steps in the investigation and treatment of epilepsy, 1911–2013
1911 Fasting noted to improve seizure control, leading to the ketogenic diet
1912 The effect of phenobarbital on epilepsy reported
1918 Air ventriculography introduced into clinical practice
1921 First trial of the ketogenic diet
1923 First hemispherectomy for epilepsy
1926 IV phenobarbital used in status epilepticus
Cerebral angiography introduced into clinical practice
1929 First human electroencephalogram published
1935 First intraoperative electrocardiogram using an EEG published
1936 First clinical EEG laboratory established
1938 First reports of the use of phenytoin
1940 First corpus callosectomy for epilepsy reported
1941 Acetazolamide introduced into clinical practice for epilepsy
1948 First temporal lobectomy with removal of the mesial structures
1953 First en bloc anterior temporal lobectomy
1954 Primidone introduced into clinical practice
1956 IV phenytoin used in status epilepticus
1957 Stereotactic atlas introduced for use in epilepsy
Operating microscope introduced into practice
1958 Ethosuximide introduced into clinical practice
1962 Depth EEG introduced into clinical practice
1963 Benzodiazepines (diazepam, chlordiazepoxide) introduced into clinical practice
IV diazepam used in status epilepticus
Acetazolamide introduced into clinical practice for epilepsy
1965 Carbamazepine introduced into clinical practice for epilepsy
1967 Valproate approved for use in clinical practice
1968 Clonazepam approved for use in clinical practice
Gamma knife used in clinical practice
1972 CT introduced into clinical practice for epilepsy
1975 Clobazam approved for use in clinical practice
1978 Piracetam approved for use in clinical practice
Antiepileptic drug monotherapy first postulated
PET scanning introduced into clinical practice for epilepsy
1982 Multiple subpial transection introduced into clinical practice
SPECT introduced into clinical practice for epilepsy
MRI introduced into clinical practice for epilepsy
1984 MRS introduced into clinical practice for epilepsy
Linac-based neurosurgery introduced
1989 A range of new drugs, licensed for clinical use over the next 25 years, based
on increasingly strict regulatory framework and data from randomized clinical trials:
vigabatrin (1989), zonisamide (1989), lamotrigine (1990), oxcarbazepine (1990), felbamate (1993),
gabapentin (1994), topiramate (1995), levetiracetam (1999), pregabalin (2004), stiripentol (2007),
rufinamide (2007), lacosamide (2008), retigabine (2010), perampanel (2012)
1995 First “epilepsy gene” discovered and the beginning of genetic investigation
1996 Cochrane epilepsy group registered in the Cochrane collaboration
1997 Vagal nerve stimulation introduced into clinical practice for epilepsy
2004 Buccal midazolam introduced into clinical practice for epilepsy
2008 RCT of trigeminal nerve stimulation in epilepsy initiated
2010 TMS trial reported favorable results in epilepsy
Deep-brain stimulation therapy for treatment of epilepsy
2011 Buccal midazolam licensed in Europe under PUMA scheme
Responsive cortical stimulation introduced into clinical practice for epilepsy
2012 eTNS system introduced into clinical practice for epilepsy
2013 Closed-loop deep-brain stimulator introduced into clinical practice for epilepsy
CT, computed tomography; EEG, electroencephalography; eTNS, external trigeminal nerve stimulation; Linac, linear accelerator; MRI, magnetic resonance
imaging; MRS, magnetic resonance spectroscopy; PET, positron emission tomography; PUMA, paediatric-use marketing authorisation; RCT, randomized con-
trolled trial; SPECT, single-photon emission computed tomography; TMS, transcranial magnetic stimulation.
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Animal screening tests
The common screening tests used for drug screening at
the Antiepileptic Drug Development (ADD) program and
related programs have a number of significant drawbacks.
First, and most important, most models are acute-seizure
models that test the antiseizure potential of a drug rather
than its antiepilepsy potential (for instance, the maximal
electroshock seizure [MES] and pentylenetetrazole [PTZ]
seizure tests). Acute seizures induced by convulsants such
as in MES and PTZ experiments do not mirror epilepsy
because they are seldom provoked and do not occur in
“normal,” nonepileptic brains. Screening drugs using the
Table 2. Areas of theory widely held or practices widely accepted at some time in the last century that are now
discredited or fallen out of favor
Theories of pathogenesis and causation of epilepsy Discredited theories/practices that were widely held/accepted:
• Genetic theories of inherited degenerative trait suggesting
that there are families in whom a wide variety of neurological disorders are
inherited together and which lead to increasing degeneration over generations
• Autointoxication suggesting that epilepsy is due to toxins from, for instance,
infection, dental decay, or fermentation from gastrointestinal bacteria
• Reflex causes of epilepsy suggesting seizures are caused by
sensory-motor triggers, pain in limbs, pathology in ear or nose, or genital stimulation
• Psychoanalytical theories of epilepsy suggesting that epilepsy is the result
of egocentricity, supersensitivity, emotional poverty, or an inherent
defect of adaptability to normal life, and the epileptic attack as a
regression to an infantile mentality
• Vascular theories of epilepsy suggesting epilepsy is due to vascular congestion
or insufficiency
Clinical theory Epileptic personality traits, such as viscosity, adhesiveness, circumlocutory,
aggressivity, enechetic, ixoid, glischroid, mental obliquity
Drug treatment Drugs now rarely used or abandoned as either too toxic or ineffective:
mesantoin, phenacemide, trimethadione, paramethodione, quinacrine
hydrochloride, methsuximide, ethotoin, phensuximide, progabide, felbamate,
tiagabine, vigabatrin, retigabine
Surgical treatment Surgical operations previously widely used and now abandoned as ineffective:
• Related to theories of autointoxication: colectomy, nasal polypectomy, adenoidectomy,
removal of teeth
• Related to theories of sexual or hormonal disturbance: castration, hysterectomy,
oophorectomy, adrenalectomy
• Related to theories of reflex causation: treatment of disease of the ears or nasopharynx,
ophthalmic operations, operations on eye muscles, the removal of tight prepuce,
resection of peripheral nerve lesions
• Related to vascular theories: carotid artery occlusion, bilateral
vertebral artery occlusion, cervical sympathectomy
Other treatment Treatments recommended but for which there is very little evidence:
• Diets (except ketogenic diet)
• Rest
• Dyes (such as brilliant red)
• Lifestyle changes such as open-air work, quiet environment,
lack of sexual activity
Prevention of epilepsy Eugenics
Table 3. Ten current areas of theory and practice that are candidates for being rejected or revised in the future
Current approaches to drug discovery
Current animal screening methods
Clinical trial methodology
Overinvestigation and overdiagnosis
Theory that the failure of response to a first and second AED implies drug resistance
Drug resistance is a result of simple variants in drug transporter or target genes
Pharmacogenomics is making a big impact on epilepsy
Surgical resection removes the “epileptic focus”
Surgical procedures (such as multiple subpial transection, corpus callosotomy, some types of extracortical resection, cortical stimulation)
Postulation that the prognosis for seizure control has not been improved by the introduction of new AEDs
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small number of current seizure models is also a process that
inevitably identifies me-too drugs and that will probably fail
to identify drugs with completely novel antiepilepsy effects.
More recently, however, recognizing the limitations of ear-
lier testing methods, the ADD program has been revised and
renamed Epilepsy Therapy Screening Project (ETSP).
Newer and more laborious models in animals with chronic
spontaneous seizures are increasingly used by the ETSP,
industry, and academic groups for screening purposes.
These models test different actions, but still old-fashioned
screening predominates, at least for initial mass screening.
We believe fresh approaches are needed.
Clinical trials
Current trial designs are also compromised in a number
of important ways, of which we sketch out some briefly
here. First, although all trials rely on changes in seizure fre-
quency (the seizure diary) as an outcome parameter, unfor-
tunately this is a most inaccurate measure. In a study by
Bonn in which the patients’ diaries were compared to video
electroencephalogram (EEG) telemetry, patients recorded
only 44% of partial seizures, and even major seizures were
missed, as were four out of five seizures at night.6 In a study
using long-term intracranial monitoring, 8 out of the 11
patients studied underestimated the real seizure rate by at
least threefold.7 One patient, who had 126 seizures recorded
per month, considered none to have occurred, and another
recorded a monthly seizure rate of 11 per month when in
fact the true figure was 102 per month. Some improvements
have been made, and small electronic wristband devices for
detecting seizures and increasing the accuracy of seizure
counts might be used in future trials, but these are not a com-
plete solution. A second fundamental problem is that drugs
are compared to placebo rather than to each other. Although
this may allow short-term biological effects to be recog-
nized, such studies provide little information to the physi-
cian who wishes to know the drugs’ relative value. Placebo
control is now also questioned from an ethical point of view
when trials delay therapy and when the delay increases the
risk of sudden unexpected death in epilepsy (SUDEP) or
other adverse consequences.8–10 Most trials have been of
adjunctive therapy, whereas the clearest assessment of any
drug would be in monotherapy, but monotherapy trials have
significant ethical and methodological defects. The current
requirement to license drugs separately as monotherapy or
as adjunctive therapy also makes no scientific sense.11
Another concern is that controlled trials generate results of
low clinical value, where a positive outcome is usually
defined as a 50% response rate, which in clinical practice
would often be considered as a treatment failure. One reason
for relying on a 50% seizure reduction is that current drugs
cannot achieve better seizure reduction in sufficiently high
numbers in formerly drug-resistant patients, which is
needed for statistical evaluation. More effective drugs of the
future may be able to achieve clinically more meaningful
75% or 100% seizure reductions in larger numbers of
patients. Long-term retention studies after clinical trials also
swamp the literature, but these almost always give inflated
treatment estimates owing to progressive enrichment of the
population (i.e., the inclusion of only those responding),
regression to the mean, and changes in concomitant therapy.
Of course, a regulatory clinical trial is not just a scholarly
affair but a global, multibillion-dollar business enterprise. A
variety of statistical and other problems, which are dis-
cussed below, have also arisen. Where enormous sums of
money are at stake, ethical problems relating to the method-
ology, recording of results, analysis and interpretation of
results, and marketing and communication can occur; and
misdemeanors at all levels may occur.
Overinvestigation and overdiagnosis
In clinical practice, overinvestigation is common and
wasteful, and it carries the risk of misdiagnosis.12 Misinter-
pretation of EEG readings by nonepilepsy specialists and
subsequent misdiagnosis of epilepsy is a case in point. The
misdiagnosis of epilepsy is often unquestionably responsi-
ble for great human suffering. Misdiagnosis rates of epi-
lepsy have been estimated to be around 30%, and this is the
result of overinterpretation of clinical signs and misreading
or misapplication of EEG findings, often by nonspecial-
ists.12 The multimedia approach to surgical investigation is
another example of a wasteful protocol if not used properly.
In a similar vein, the overapplication of advanced imaging
carries the risk of nonspecialists diagnosing minor varia-
tions as pathological that are in fact incidental. Such over-
diagnosis is also not necessarily misdiagnosis, but
incidental or unimportant findings can lead to personal,
financial, and social disadvantage. What is really needed in
the application of all investigatory modalities is clear and
concise health technology assessment, which balances the
advantages and drawbacks of tests in different clinical set-
tings.
Failure of response to a first and second AED implies
drug resistance
It has become a recent mantra that, if epilepsy fails to
respond to a first and second antiepileptic drug (AED), then
the long-term prognosis of the epilepsy is poor, and that the
epilepsy is “drug resistant.”13 This view is plainly too pes-
simistic. Careful long-term studies have shown that up to
50% of patients who did not become seizure free with their
first two AEDs enter long-term seizure remission with a
change of AED treatment.14 It has been known for years that
many cases of epilepsy remit early in the course of the con-
dition and that the longer the condition remains active, the
worse the prognosis. But to ascribe this to the “number of
drugs taken” and to conflate this with “drug resistance” are
errors. Short-lasting epilepsy is going to be treated with
fewer drugs than long-lasting epilepsy, and the association
of outcome and number of drugs is not likely to be causal.
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Many types of epilepsy have a good inherent prognosis and
remit regardless of treatment—this is true of benign syn-
dromes and acute symptomatic seizures; on the other
hand, other types fail to remit whichever treatment is
applied—this is true of severe syndromes and the like. Prog-
nosis and natural history are much more likely to be deter-
mined by these biological factors than a spurious factor
such as the number of drugs tried. Misdiagnosis is another
important factor at this early stage that affects these appar-
ent statistics, and it has been estimated that up to 30% of
early cases of apparent seizures are in fact not epileptic at
all.12 Furthermore, it makes no sense to believe that failure
to respond to a drug with one mechanism of action has any
influence on whether an epilepsy will respond to another
with a different mechanism of action. Finally, it is common
in clinical experience to see response to drug changes even
in chronic epilepsy, and formal studies have repeatedly
shown this, with very good responses obtained when
rational approaches to the treatment of chronic epilepsy are
applied.
Drug resistance is a genetic trait
One commonly mentioned theory is that drug resis-
tance is a genetic trait and that variants (polymor-
phisms) in the genes coding for drug transporters, for
instance for P-glycoprotein, or for drug targets, for
instance for the GABA or sodium channel, are responsi-
ble for the lack of response in focal epilepsy.15–17 In
fact, no polymorphism of genes involved in regulating
AED transporter activity across brain cell membranes
has been shown consistently to have any marked effect
on therapy. Moreover, there are a number of obvious
and crucial objections to such theory. Many drugs are
not transported, or are only weakly so, by P-glycopro-
tein, and there is also marked phenotypic variation, no
known saturable kinetic effects, and the expression of
the gene is under strong environmental influence. Not
all drugs act at the same brain receptors, so the target
hypothesis cannot be universally applied for this reason
alone. Also, other aspects affect response but cannot
have any relationship to drug target or transporters, for
instance: etiology of the epilepsy, epilepsy syndrome,
extent or position of a brain lesion, environmental fac-
tors such as nutrition, lack of sleep, hepatic enzyme
induction, drug receptor regulation, drug dose, pharma-
cokinetics, and comedication. In fact, none of the com-
monly proposed theories is able to convincingly explain
drug resistance in focal epilepsy.4,5
Pharmacogenomics is making a big impact on epilepsy
In 2000, the head of a major pharmaceutical company
informed the epilepsy community that “pharmacogenetics
will be widespread in epilepsy within 3 to 5 years.” This
was overoptimistic. Articles are still frequently written on
the “promise of pharmacogenetics,” but as yet the concrete
benefits are conspicuous by their absence except perhaps in
detecting hypersensitivity to individual AEDs, mostly car-
bamazepine in people from Asia.18–24 In our view, the com-
plexity and multifactorial nature of success or failure of
antiepileptic drug treatment render it unlikely that simple
single pharmacogenetic mechanisms, at least as they are
currently conceived, do have any major impact on therapy.
The widely hyped “tailoring” of drug therapy to an individ-
ual on the basis of that person’s genetic makeup sadly seems
a long way off.
Surgical resection removes the epileptic focus
Much of contemporary surgical practice is predicated on
the thought that in partial epilepsy there is a discrete “focus”
that is limited in anatomical range, and that fully resecting
this focus can “remove” the epilepsy. In a minority of
patients this is the case, for instance, in patients with small
cortical lesions, particularly in the primary motor-sensory
areas. However, in the majority of types of epilepsy, a large
body of evidence demonstrates this to be a simplistic and
erroneous view, which might be termed the phenological
fallacy of epilepsy surgery. Neurophysiological evidence,
both experimental and clinical, shows that the seizures of
mesial temporal lobe epilepsy arise from activation of a
whole network of cells (in the latest jargon—a neural net-
work), starting sometimes simultaneously in different parts
of the network or arising in varying alternative parts of the
network. The fact that the clinical features of a temporal
lobe seizure involve many aspects that are not part of tem-
poral lobe function (motor aspects, loss of consciousness,
etc), even when there is pathology in the hippocampus, is
further evidence of involvement beyond the hippocampus.
This is not caused by “spread” but by much more sophisti-
cated reciprocal activation in the epileptogenic areas. Clini-
cal depth electrode studies frequently show different seizure
onsets in different parts of the limbic system. Widespread
connectivity changes have been repeatedly demonstrated
extending beyond the temporal lobe, and neurochemical
changes are measurable in locations outside the temporal
lobe. Furthermore, after temporal lobectomy, three clinical
phenomena need explanation. Auras often remain even if
complex partial seizures are suppressed. Seizures recur in
an important minority of patients in the years after temporal
lobectomy. Many patients require continued drug treatment
after full surgical removal of the focus. The most parsimo-
nious explanation of these phenomena is that seizures are a
system phenomenon and that wide limbic areas, not a dis-
crete focus, underpin the seizures. The temporal lobectomy
simply removes part of this system, and resective surgery
does not fully eliminate the widespread connectivity
changes responsible for seizures. Successful surgery does
degrade the ability of the system to generate seizures but
certainly does not resect a focus. This is of obvious impor-
tance clinically, because increasingly complex multimedia
investigations are directed at identifying the “epilepsy
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focus.” Despite these concerns, surgery is of course neces-
sary and very valuable in selected circumstances, but by vir-
tue of the complex mechanisms underlying seizure
occurrence, the possibility exists of seizure recurrence on
and off AEDs during follow-up,25 and the concept of the
discrete focus cannot be applied in many types of focal epi-
lepsy.
Surgical procedures
Corpus callosotomy, multiple subpial transection, and
some types of extratemporal resections are surgical proce-
dures still carried out, but they have not been subject to any
controlled assessment and they have significant drawbacks
and risks. Randomizing patients to surgery plus medical
treatment versus standard medical treatment alone would be
one option, or delayed surgery. Wilder Penfield, a pioneer
of epilepsy surgery, carried out a study in which patients
were randomized to brain surgery or sham surgery,26 but
this would not meet modern ethical standards. Given the
dramatic nature of surgery and the presurgical examina-
tions, it is likely that surgical interventions in epilepsy will
trigger a substantial placebo response similar to that seen in
drug trials (as Penfield demonstrated). If one takes a very
pessimistic and possibly too harsh view, it is likely that in
the future some of our surgical treatments may be consid-
ered as obsolete as some of the operations mentioned in
Table 2. The same might apply to more recent procedures
such as certain forms of cerebral and peripheral stimulation.
One recent well-performed trial of an implanted brain stim-
ulator, for example, illustrates the issues of double-blind tri-
als in cerebral stimulation. Following implantation of the
stimulator and leads and prior to stimulation treatment in
either the treatment or the sham group, both groups experi-
enced a mean percent reduction in the observed number of
seizures (25% treatment and 20% sham) and a median per-
cent reduction in the observed number of seizures (33%
treatment and 30% sham). Whether this is an effect of the
surgical procedure or anesthesia, lead implantation, regres-
sion to the mean, or placebo is not known. While undergo-
ing treatment in the next phase of the trial, 76% of subjects
in the treatment group and 70% in the sham group reported
a decrease in seizures during the blinded evaluation phase.
A benefit in seizure reduction was, however, seen in the sub-
sequent open-label long-term observation phase.27 A dou-
ble-blind trial of a new AED showing no difference in
seizure outcome during the blinded evaluation period would
not have been considered as evidence for efficacy.
The prognosis of epilepsy has not improved
It is often stated that the prognosis of epilepsy has not
improved in recent decades. This is despite the fact that mil-
lions of dollars have been spent on demonstrating the anti-
seizure effect of modern drugs and that a range of new drugs
has been licensed. It is true that no large-scale study has
been carried out that confirms or refutes this proposition,
but with the large number of new therapies made available
in recent years, and the indisputable advances in the science
of epileptology, including surgery and neuroimaging,
it would be surprising if the medical prognosis has not
improved. Even if individual drugs result in seizure control
in only a small percentage of patients, the additive effect of
a number of these drugs tried in turn results in a markedly
improved overall prognosis.28 Furthermore, there is plenty
of anecdotal evidence that prognosis has been transformed.
We are old enough to remember the common clinical expe-
riences of 40 years ago at a time when there was widespread
use of sedative drugs, when the treatment response was
clearly worse than that now.
Why DoWe Get It Sometimes
Wrong?
Epilepsy has made tremendous progress in the past cen-
tury. We have attempted to list in Table 1 some landmarks
in the investigation and treatment of epilepsy, and because
of these, there is no doubt that the prospects for persons
with epilepsy have greatly improved. As we point out ear-
lier, too, societal changes in recent years have greatly ben-
efited people with epilepsy, and indeed the evolution of
change in public attitude and societal practice can be con-
sidered even more important than the scientific and medi-
cal changes.
However, we hope also to show that theories and prac-
tices in the past are often later dismissed as misguided, and
the same is likely to apply today. The examples we have
chosen are perhaps particularly egregious, and many others
could have been selected.
Compiling lists is less important than trying to understand
the root causes of such solecisms. Sometimes, appropriate
research has not been carried out (for instance, in relation to
assessing the prognosis of epilepsy), but often practice or
theory is based on inaccurate research. Identifying the cause
of inaccuracy is not necessarily simple. Often various fac-
tors are relevant, and here we speculate briefly on some of
the more fundamental root causes that promote the adoption
of flawed theory and practice.
The first point to make is that scientific theory and prac-
tice are prone to fashion. They are strongly influenced by
the societal beliefs and mores of the time. In other words,
science is relative and certainly not objective—an important
point to emphasize. The focus on degeneration in the early
part of the 20th century is one example. The theories of the
neurological trait and of degenerative genetic influences
imply a manifestation of this fashion, which affected many
different intellectual areas in social studies, art, and science.
The same applied to a variety of fashionable psychological
theories that were often shared between medicine, the arts,
and politics. The more recent fashions for cerebral func-
tional imaging and the related phrenological fallacy are
partly the result of the public appetite for visual display and
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visual imagery of what “the brain is like.” Raymond Tallis
has effectively criticized this as “neuromania.”29
The overwhelming influence of economics, too, is
another example of how the priorities of science are deter-
mined predominately by social forces—in the field of epi-
lepsy, there are many examples of this in relation to the
pharmaceutical industry, regulation, and the conduct of
university research (see below). Funding issues and under-
funding of epilepsy research push investigators toward
small-sample studies with narrow foci. It is not fair to blame
investigators for trying to do what they can with limited
resources, and one should be thankful—and we are—for
what has been done despite all the issues surrounding the
practicalities of academic research. In the field of investiga-
tion and clinical practice, financial considerations are para-
mount. In the United States, a country of 300 million people
with a largely free-market approach to medicine, 15 million
nuclear medicine scans, 100 million computed tomography
(CT) and magnetic resonance imaging (MRI) scans, and
almost 10 billion laboratory tests are carried out each year.30
Often, these are essentially fishing expeditions, and because
no patient is perfectly “normal,” clinicians tend to find a lot
of fish. Societal fashion and trends are not necessarily detri-
mental to medicine, of course, and the liberal political
climate has encouraged social advancement in epilepsy in
many countries. That scientific knowledge is relative is an
obvious truism, but one that is sometimes forgotten in over-
inflated claims of scientific neutrality.
A second point is that the mere application of scientific
method does not imply accuracy. Many scientific theories,
supported by scientific study, have produced “scientific”
conclusions that later were shown to be utterly wrong
—“bad science,” as this has been dubbed.31 Increasing criti-
cism has been made, not least from the editors of scientific
journals frustrated by the profusion of bad science. Richard
Horton, editor of the Lancet, recently wrote that much of the
scientific literature—indeed, perhaps half—is simply
untrue.32 The problem is often methodological, with poorly
drafted scientific questions or poorly conducted scientific
method. Horton mentions “small sample sizes, tiny effects,
invalid exploratory analyses, flagrant conflicts of interest,
an obsession in pursing fashionable trends of dubious
importance. . .. The apparent endemicity of bad research
behaviour is alarming. In their quest for telling a competing
story, scientists too often sculpt data to fit their preferred
theory of the world or they retrofit hypothesis to fit their
data.” John Ioannidis in a widely cited paper in 200533 ana-
lyzed 49 of the most highly regarded research findings in
medicine over the previous 13 years and compared the 45
studies that claimed to have uncovered effective interven-
tions with data from subsequent studies with larger sample
sizes. He found that 16% were contradicted, 16% had
effects that were smaller than in the initial study, and only
44% were replicated. This is not a good record. Another
point concerns meta-analysis and other large data projects.
Jeffrey Drazen, editor of the New England Journal of Medi-
cine, has pointed out that a person not involved in the
generation or collection of data may not understand the
choices made in defining its parameters.34 In joining up dif-
ferent studies, for instance, in meta-analysis, the data may
be collected from heterogeneous study populations with dif-
ferent eligibility criteria, different methods of data collec-
tion and analysis, and different treatments. Drazen wrote
that “a new class of research person has emerged,”whom he
calls provocatively “research parasites.” These are “people
who had nothing to do with the design and execution of the
study but use another group’s data for their own ends.” In
epilepsy, meta-analyses abound, and although the early
analyses comparing clinical trials were important and justi-
fied, their proliferation into surgical and psychosocial fields,
for instance, where studies are often extremely heteroge-
neous, has led to poor standards and poor methodology,
much as Drazen, Ioannidis, and Horton describe.
The lack of reproducibility and reliability of results in
biomedical research is another great concern. This has been
thought to result from sloppy methodology of the sort listed
above; wish fulfilment of researchers who are dedicated to
finding one result and who retrofit, massage, or otherwise
manipulate data; or, in some cases, actual fraud. We are
aware of examples of each of these in the field of epilepsy.
Where large datasets are involved, for instance, in genetics,
the complexity of the statistical analysis lends itself to
manipulation, and the lack of reproducibility of genetic data
is a cause of particular concern. The issues of reliability of
pharmaceutical drug trials, too, is worrisome, given the very
large investment of time and money and the effects failed
trials can have on companies and shareholders. Pharmaceu-
tical medicine is just one area where science, marketing,
and commercial factors are intimately intertwined, and their
close relationships have been a matter of public disquiet.
It is also important to realize that the process of medicine,
and the context in which it is practiced, determines its direc-
tion. The impact of context and bureaucracy should not be
underestimated, and the consequences are sometime unin-
tended or perverse. The strengthening of rules for drug trials
in epilepsy is an example. Although changes were necessary
to establish criteria for effect and safety, the pendulum of
current regulations may have swung too far toward unneces-
sary overregulation (one example is the need to demonstrate
efficacy in both monotherapy and polytherapy, when there
is no scientific evidence of synergy). Drug discovery is now
probably seriously hampered and possible to undertake only
by the largest multinationals. The consequences are a lack
of innovation and inflation of costs, and there is also no evi-
dence that safety is enhanced, as some recent substantial
adverse events involving new drugs, such as retigabine or
vigabatrin for treatment of focal seizures, demonstrate.
However, to be fair, vigabatrin is still a first-choice medica-
tion for children with epilepsy due to tuberous sclerosis and
among the top choices in West syndrome, even if for lack of
Epilepsia Open, 1(3-4):76–85, 2016
doi: 10.1002/epi4.12011
83
The Right and theWrong of Epilepsy
better treatment. Another example is the extraordinary mul-
tiplication of medical journals, which has occurred primar-
ily because journal publishing in the online age can make a
quick profit. The result is that poorer work, which would not
previously have passed muster, is able to find a home in a
journal that will accept it. The academic world is now awash
with inconsequential and often inaccurate science and a ver-
itable barrage of white noise. Other issues relating to medi-
cal publishing, and to the gaming of medical authors in
publishing their work, have recently been reviewed by the
ex-editor of The BMJ.35 The increasing tendency of univer-
sities to base their decisions about funding and about indi-
vidual promotions on publication record fuels this gaming
around medical publishing.
Finally, to impropriety
Medical scientists are assumed to have high standards,
but in a small number of cases, this assumption has been
shown to be unjustified.36 We have come across individuals
whose results seem untrustworthy and whose findings are
never reproduced. Of course, not all unvalidated discoveries
are dishonest or useless, and progress can only be made
when there are both successes and failures. Yet, there is a
spectrum of behaviors ranging from unconscious bias to
deliberate fraud. In some cases, data massaging occurs, such
as ignoring outliers or results that do not conform, or results
are over interpreted, justified by the thought that “my theory
must be right.” In other cases, the fraud has been more con-
scious, often stimulated by the need to obtain more grant
funding. We are aware of high-profile figures reporting
results that seem highly unlikely and that are never repli-
cated. In modern epileptology, this seems to occur espe-
cially in fields where big data are easy to misrepresent. A
recent survey found that 0.3% of researchers falsified data,
6% failed to present data that contradicted their results, 8%
circumvented minor aspects of human subject requirements,
13% overlooked others’ questionable interpretation or
flawed data, and 16% changed study methodology in
response to funding source pressure.36 It has also been esti-
mated that approximately 10–20% of all research and devel-
opment (R&D) funds are spent on questionable studies
characterized by misrepresentation of data, inaccurate
reporting, and fabrication of experimental results.37 A meta-
analysis of studies similarly showed that 2% of all scientists
admitted to having fabricated, falsified, or modified data,
and more than 33% admitted other questionable research
practices.38 The epilepsy journals, as with others, are littered
with their fair share of reports of the success of surgical and
medical treatments that cannot possibly be correct, and for
these various reasons, it has been claimed that massive mis-
information exists in the domain of scientific research. This
has become of increasing public concern.39–44 Goldacre
wrote of a litany of dubious practices in relation to pharma-
ceutical trials including missing data from negative trials
that were suppressed, the lack of transparency of data, the
problems with outsourcing volunteer studies, statistical
errors in trials, the medicalization of behaviors to create dis-
eases that then can be treated, the sophistication of market-
ing of drugs, the nature of the connections between the
academic medical community and commercial interests.45
Many of these issues may have applied as much to epilepsy
as to other conditions.
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